1. No category

08.00
REGISTRATION & COFFEE
08.20
Opening Speech by:
Barrett J. Rollins, MD, PhD Linde Family Professor of Medicine at Harvard Medical School, Chief Scientific Officer at Dana-Farber Cancer Institute
08.45
Deal Making
Co-Chaired by:
Anne Altmeyer, Vice President, Business Development & Licensing, Oncology, Novartis
Pharmaceuticals
Dov Hass, Associate, Morgan, Lewis & Bockius LLP
Panellists:
Dennis Purcell, Founder and Senior Advisor, Aisling Capital
Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo Inc.
Guillaume Vignon, Director of Global BD Oncology, Merck Serono SA
Howard J. Fingert, Senior Medical Director, Business Development & Clinical Intelligence,
Takeda Oncology
Ji Li, Vice President, Business Development and Licensing, Merck & Co., Inc.
John Gustofson, Senior Director, Venture and Early Stage Collaboration, AbbVie
Steven Tregay, Chief Executive Officer, Forma Therapeutics
Wendy Dwyer, Vice President, Corporate Business Development, Ipsen Bioscience
09.45
10.45
NextGen Immunotherapeutics
Co-Chaired by
Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis SA
Panellists:
Doug Plessinger, VP, Clinical and Medical Affair, Argos Therapeutics, Inc.
Frank Gleeson, Chief Executive Officer, Fusion Pharmaceuticals
Gil Beyen, Chairman and CEO, Erytech Pharma
Greg Mayes, CBO, Advaxis Inc.
Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer
Dragan Cicic, CMO, Actinium Pharmaceuticals. Inc.
Marc Mansour, CEO, Immunovaccine Technologies
Paul Higham, Managing Director, immatics biotechnologies GmbH
Robert Pierce, Chief Scientific Officer, Oncosec Medical
COFFEE BREAK
Emerging Companies Track
08.45
Cell Source Ltd.
08.55
Office of Therapeutics Alliances, NYU School of Medicine
09.05
Pelican Therapeutics
09.15
Rexahn Pharmaceuticals, Inc.
09.25
SolaranRx, Inc
09.35
tba
09.45
tba
09.55
tba
10.05
tba
10.15
tba
10.25
tba
10.35
tba
Presenting Companies TRACK A
11.00
12.00
12.45
Gene & Cell Therapy
Co-Chaired by:
Maxim Jacobs, Senior Healthcare Analyst, Edison Group
Mike Rice, Senior Consultant, Defined Health
Panellists:
Madhusudan Peshwa, Executive Vice President, Cellular Therapies, MaxCyte, Inc.
Mike Khan, CMO, Silence Therapeutics
Robert Dillman, Vice-President of Oncology, NeoStem, Inc.
Peter Hoang, Senior Vice President BD & Strategy, Bellicum Pharmaceuticals, Inc.
Peter Sandor, VP Global Marketing, TA Head Oncology, Amgen
Personalized Medicine & Diagnostics
Co-Chaired by:
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Rowan Chapman, Managing Director, Ventures, GE Healthcare
Panellists:
Bernhard Sixt, President and CEO, ImmunID
Claudio Carini, Global Head of Immunology & Biomarkers, Pfizer
Lisa Ricciardi, SVP, Corporate & Business Development, Foundation Medicine
Thomas Tulip, President and CBO, Navidea Biopharmaceuticals
11.00
Berg LLC
11.15
BerGenBio AS
11.30
Nanobiotix SA
11.45
ImmunoVaccine Inc.
12.00
Enumeral Biomedical Holdings, Inc.
12.15
tba
12.30
tba
NETWORKING LUNCH
Presenting Companies TRACK B
Presenting Companies TRACK C
13.45
Actinium Pharmaceuticals
Fusion Pharmaceuticals
14.00
Advaxis Inc.
Casi Pharmaceuticals, Inc.
14.15
Argos Therapeutics, Inc.
MaxCyte, Inc.
14.30
ERYTECH Pharma SA
Novogen Ltd
14.45
IMMUNE Pharmaceuticals
OncoSec Medical, Inc.
15.00
Navidea Biopharmaceuticals
XEME Biopharma Inc
15.15
CBM
tba
15.30
CEL-SCI
tba
15.45
COFFEE BREAK
16.00
Public & Private Partnerships
Co-Chaired by:
Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society
Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute
Panellists:
Belen Carrillo-Rivas, Senior Director, Pfizer
Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Fiona An, Senior Vice President, The Multiple Myeloma Research Foundation
Issi Rosen, Director, Strategic Alliances, The Eli and Edythe L. Broad Institute of Harvard and
MIT
Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Steven Young, President, Addario Lung Cancer Medical Institute
17.00
Investment Roundtable
Co-Chaired by:
Beth Jacobs, Managing Partner, Excellentia Global Partners
Stuart Barich, Managing Director, Oppenheimer & Co. Inc.
Panellists:
Christopher Earl, Senior Advisor, Merck Research Laboratories Ventures
Daniel Teper, CEO, IMMUNE Pharmaceuticals
Jens Eckstein, President, S.R.One Limited
John DeYoung, Vice President, Worldwide Business Development, Pfizer
Philippe Muaberna, CFO, Nanobiotix
Robert Urban, Head, Johnson & Johnson Innovation
Todd Foley, Managing Director, MPM Capital
18.00
NETWORKING RECEPTION
19.00
END OF THE FORUM
Presenting Companies TRACK D
16.00
Silence Therapeutics
16.15
immatics biotechnologies GmbH
16.30
ImmunID
16.45
NeoStem, Inc.